GET DAILY SIGNALSWhy Is Caris Life Sciences (CAI) Stock Down -4.61% Today?
Key Takeaways
- CAI shares were down roughly 4.61% in Thursday's session, extending a sharp multi-day selloff following the company's third-quarter earnings report.
- The primary catalyst is an earnings-driven move: CAI reported Q3 EPS of $0.05, missing consensus estimates of $0.16, even as revenue beat expectations.
- Profitability concerns were the core driver, with net income and adjusted EBITDA declining year over year on higher expenses, overshadowing 27% revenue growth.
- Secondary drivers include profit-taking after a steep prior rally and valuation concerns, as the stock had surged well above earlier trading levels before the pullback.
- Broader sentiment around richly valued, early-stage precision-medicine names has added to the selling pressure in recent sessions.
- Traders are watching whether the stock stabilizes near key technical support levels and how analysts respond to the margin miss in the coming days.
- For additional detail on this company, explore Price Targets, Earnings, and Forecast pages on Tickeron.
- To see how AI-driven strategies are positioning in this environment, visit the Trending AI Robots page.
Opening Summary
Caris Life Sciences, Inc. (CAI), a TechBio company focused on molecular profiling and precision-medicine diagnostics, extended its recent decline on Thursday. The stock fell about 4.61%, or $1.20, to $24.83, compared with a prior-session close of $26.03. The drop reflects continued market reaction to third-quarter results that showed robust revenue growth but a notable miss on profitability, as higher expenses weighed on the bottom line.
Earnings Results and Guidance
The central catalyst behind the slide is CAI's third-quarter earnings report. The company posted adjusted earnings of $0.05 per share, well short of the roughly $0.16 per share analysts had expected. While total revenue climbed 27% year over year to $275.36 million — driven by higher clinical case volume and improved average selling prices in molecular profiling — the profit miss took center stage. Net income attributable to common shareholders fell to $15.25 million from $24.32 million a year earlier, and adjusted EBITDA declined to $44.42 million from $51.20 million.
The company did raise its full-year 2026 revenue guidance to a range of $1.04 billion to $1.05 billion, implying growth of roughly 28% to 29%, and reaffirmed its outlook for about 20% growth in clinical therapy selection volume. However, the market's focus remained on the earnings shortfall and margin compression, which overwhelmed the more constructive revenue picture.
Profit-Taking and Valuation Pressure
The earnings disappointment triggered an unwind in a stock that had run up substantially in prior months. CAI had rallied sharply from earlier levels, leaving it trading at a rich valuation relative to its fundamental estimates. With profitability for fiscal 2026 still uncertain and the shares carrying a premium multiple, investors used the margin miss as a cue to lock in gains. This kind of "sell the news" reaction is common when high-multiple growth names deliver revenue beats but stumble on earnings, and it has kept the stock under pressure across multiple sessions.
Market Context and Trading Activity
The decline has come on heavy trading volume, with turnover in recent sessions running well above the stock's typical daily average, indicating conviction behind the selling rather than a thin, low-liquidity drift. The move is largely company-specific rather than a broad market event, driven by the earnings and valuation dynamics described above. Technical weakness has also compounded the slide, as the shares broke below recent support levels and moved decisively lower from their prior trading range, reinforcing momentum-driven selling among short-term traders.
What Comes Next for CAI
Looking ahead, investors will be monitoring whether CAI can demonstrate a clearer path to profitability while sustaining its revenue momentum. Key watchpoints include the company's next quarterly results, any updates to full-year 2026 guidance, and whether the raised revenue outlook translates into improving margins. Analyst reactions will also matter, as several firms have maintained positive ratings while acknowledging the valuation and profitability concerns. Risks include further margin compression, execution challenges in scaling its diagnostic and pharma-services offerings, and the possibility that high expectations built into the stock continue to reset lower.
Trending AI Robots
Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the strongest performers under current market conditions are featured in the curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving traders a way to explore data-driven approaches to navigating volatile markets. Discover which AI strategies are leading the pack today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CAI in upward trend: price may jump up because it broke its lower Bollinger Band on November 05, 2026
CAI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 10 of 11 cases where CAI's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +3.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAI advanced for three days, in 46 of 67 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Bearish Trend Analysis
The 10-day RSI Indicator for CAI moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 7 similar instances where the indicator moved out of overbought territory. In 6 of the 7 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 14 of 17 cases where CAI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 82%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CAI as a result. In 24 of 28 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for CAI turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 10 similar instances when the indicator turned negative. In 10 of the 10 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
CAI moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. CAI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.431) is normal, around the industry mean (2.788). P/E Ratio (2.717) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (9.059). Dividend Yield (0.021) settles around the average of (133.911) among similar stocks. P/S Ratio (8.084) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in the business of leasing international intermodal marine cargo containers
Industry Biotechnology
Advertisement